What's Going On With Intensity Therapeutics Stock Friday?
Intensity Therapeutics, Inc. shares are tumbling on Friday following the announcement of a 1-for-25 reverse stock split to increase the per-share trading price and comply with Nasdaq listing requirements.
The stock’s decline comes as broader markets are experiencing gains, with the S&P 500 up 0.24% and the Nasdaq rising 0.29%.
The reverse stock split, approved by shareholders in October 2025, is set to take effect at 4:01 p.m. Eastern Time on February 18, 2026, with trading on a post-split adjusted basis beginning on February 19, 2026. This move will reduce the number of outstanding shares from approximately 63.3 million to about 2.5 million, which is expected to help the company regain compliance with Nasdaq’s minimum bid price requirement.
In addition to the split, Intensity Therapeutics is focused on its lead product candidate, INT230-6, which is designed for direct intratumoral injection.
The company aims to leverage its proprietary DfuseRx technology to enhance the effectiveness of cancer therapies.
The broader market is experiencing positive momentum, with the Technology sector gaining 1.47% today. Despite this, Intensity Therapeutics’ stock is down, indicating that company-specific factors are influencing its performance.
Technical Analysis
The stock is currently trading 30.8% below its 20-day simple moving average (SMA) and 36.1% below its 50-day SMA, indicating significant weakness in its short-term trend.
Over the past 12 months, shares have decreased by 87.94%, and they are positioned closer to their 52-week lows than highs, suggesting ongoing challenges for the company.
The RSI is at 46.41, which is considered neutral territory, while the MACD is above its signal line, indicating a potential bullish signal. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.
- Key Resistance: 50 cents
- Key Support: 20 cents
Earnings Outlook
Looking further out, the next major catalyst for the stock arrives with the March 12, 2026, earnings report.
- EPS Estimate: Loss of 5 cents (Up from Loss of 22 cents YoY)
- Revenue Estimate: $0.00 M
INTS Price Action: Intensity Therapeutics shares were down 26.70% at $0.27 at the time of publication on Friday. The stock is near its 52-week low of $0.18.
Photo by jittawit21 via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc reaches fresh 16-month lows ahead of CPI data
Arthur Hayes forecasts $1 million Bitcoin by 2030, links target to AI debt risks
AI valuation divergence intensifies! Anthropic IPO: Enthusiastic Silicon Valley bids $2 trillion, while a cautious Wall Street only recognizes $1.5 trillion
The valuation debate surrounding Anthropic’s IPO is exposing a pricing gap between Silicon Valley and Wall Street. Silicon Valley venture capitalists are still betting heavily on AI growth at high valuations, with some investment banks discussing an early valuation of around $2 trillion. Meanwhile, Wall Street public market institutions are focusing on high interest rates, capital expenditure on computing power, and ongoing financing pressures, and are leaning toward a $1.5 trillion valuation.
Micron (MU.US) Q4 earnings call: Management declares "No sign of supply-demand balance," 75% of shipments for next year already locked in; 2028 expected to be tighter than 2027
Micron Technology (MU.US) management expressed optimism during the Q4 earnings call, stating that AI-driven memory demand remains strong and that supply and demand will remain tight in 2027 and 2028.
Crypto prices
More
